Mereo BioPharma Group (NASDAQ:MREO – Get Rating) had its price target decreased by Needham & Company LLC from $10.00 to $5.00 in a report published on Monday morning, Stock Target Advisor reports. Needham & Company LLC currently has a buy rating on the stock.
Several other research analysts have also recently weighed in on the company. Zacks Investment Research cut Mereo BioPharma Group from a buy rating to a hold rating in a research report on Thursday. SVB Leerink reissued a buy rating and set a $8.00 price objective on shares of Mereo BioPharma Group in a report on Friday, April 1st. Finally, BTIG Research restated a buy rating and set a $8.00 target price on shares of Mereo BioPharma Group in a research report on Friday, May 13th.
Shares of Mereo BioPharma Group stock opened at $0.57 on Monday. The company has a current ratio of 7.92, a quick ratio of 7.92 and a debt-to-equity ratio of 0.16. The stock has a 50-day simple moving average of $0.71 and a 200-day simple moving average of $1.18. Mereo BioPharma Group has a 52-week low of $0.30 and a 52-week high of $3.65.
Mereo BioPharma Group Company Profile (Get Rating)
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor.
- Get a free copy of the StockNews.com research report on Mereo BioPharma Group (MREO)
- This Isn’t A Buyable Bottom For Stocks
- Macys Stock is Ready to Buy
- First Solar Stock is Ready to Shine
- Insiders And Institutions Drive Consolidated Edison To New Highs
- MarketBeat: Week in Review 5/30 – 6/3
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.